Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Latest "Placebo Hepatitis Virus Infection" News Stories

04:22 EDT 23rd April 2014 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 6,800+

Extremely Relevant

FDA Approves New Treatment for Hepatitis C

The Food and Drug Administration (FDA) announces that it has approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with the hepatitis C virus have no symptoms of

Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection

T cells specific for hepatitis C virus (HCV) have been reported in some individuals who have been repeatedly exposed to virus, yet have never had detectable HCV or HCV-specific antibodies. These findings suggest that T cells in these individuals may...

FDA approves new treatment for hepatitis C virus

The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection.

FDA Approves Olysio (simeprevir) for Hepatitis C Virus

November 22, 2013 -- The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to...

Newly found tactics in offense-defense struggle with hepatitis C virus

(University of Washington) The hepatitis C virus (HCV) has a previously unrecognized tactic to outwit antiviral responses and sustain a long-term infection. It also turns out that some people are genetically equipped with a strong countermeasure to...

Idenix Pharma begins Phase II combination trial to treat hepatitis C virus infection

US-based biopharmaceutical company Idenix Pharmaceuticals has started patient enrollment in the Phase II HELIX-2 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination therapy of samatasvir, simeprevir and TMC647055 for...

Hepatitis C infection varies widely among different Hispanic groups in the U.S.

The first study of hepatitis C infection among different Hispanic groups in the U.S. has found that infection with the virus varies widely, with Puerto Rican Hispanics much more likely than other groups to be infected. The study, led by researchers a...

Study reveals prevalence of hepatitis C infection varies widely among Hispanics

The first study of hepatitis C infection among different Hispanic groups in the U.S. has found that infection with the virus varies widely, with Puerto Rican Hispanics much more likely than other groups to be infected. The study, led by researchers a...

Janssen hepatitis C drug approved by US FDA

Janssen's chronic hepatitis C drug, Olysio, has been approved for use in the United States by the Food and Drug Administation (FDA).Olysio (simeprevir) is a protease inhibitor that blocks a specific protein needed by the hepatitis C virus to replicat...

Hepatitis B Vaccination Spurs Virus Mutation Rate

The rate of mutations that allow the hepatitis B virus (HBV) to evade the vaccine used to prevent infection has almost doubled since 1992, when a nationwide infant vaccination campaign against HBV was begun in China, according to a new study (Bian T...

Citations Highlight Promising New Drugs for Hepatitis C Infection

The U.S. Centers for Disease Control and Prevention has recently revised its guidance on testing for infection with hepatitis C virus (HCV). Testing for anti-HCV, recommended for known at-risk groups for the past 15 years (and, in 2012, suggested as routine in the birth cohort 1945-65, the so-called “baby boomers”) does not distinguish between past […]The post Citations Highlight Promisi...

Can low-dose interferon prevent relapse of hepatitis C virus infection?

(Mary Ann Liebert, Inc./Genetic Engineering News) Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals. Low-dose o...

Revized clinical practice guidelines for management of hepatitis C virus infection from EASL

The European Association for the Study of the Liver has today published its revized Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection (HCV), which supersede the previous version published in 2011 and are designed to...

Revised clinical practice guidelines for management of hepatitis C virus infection from EASL

The European Association for the Study of the Liver has today published its revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection (HCV), which supersede the previous version published in 2011 and are designed to...

Monthly News Roundup - December 2013

Sovaldi: Breakthrough Therapy Approved for Hepatitis C Virus The U.S. Food and Drug Administration has approved Gilead’s Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is part of a new paradigm of treatment,...

U.S. FDA approves J&J hepatitis C pill

(Reuters) - U.S. regulators on Friday approved the use of Johnson & Johnson's Olysio, also known as simeprevir, as a treatment for chronic infection with the liver-destroying hepatitis C virus.

Pharma refuses to ensure access to lifesaving Hepatitis C treatment at global meeting

Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies....

Gilead’s $1,000 per day Hep C drug approved

Gilead’s Sovaldi has gained FDA approval as a potential cure for hepatitis C after the US regulator sped up its review time for the ‘breakthrough’ pill. Sovaldi (sofosbuvir) is now licensed to treat chronic hepatitis C virus (HCV) infection in the US. According to Gilead most patients will be treated with the $1,000-a-day drug for 12 weeks, resulting in a total list price of $84,000. Sovaldi...

Structure of virus identified that could lead to hepatitis C vaccine

Rutgers University scientists have determined the structure of a hepatitis C surface protein, a finding that could assist in the development of a vaccine to halt the spread of the the deadly disease that has infected 3.2 million Americans.Joseph Marc...

FDA approves Gilead's breakthrough hepatitis C drug

(Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi, also known as sofosbuvir, as a treatment for chronic infection with the liver-destroying hepatitis C virus.

FDA approves Gilead's $1,000-a-day hepatitis C pill

(Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi as a potentially easier cure for chronic infection with the liver-destroying hepatitis C virus.

Idenix starts Phase II combination therapy study for treatment of hepatitis c virus infection

Idenix Pharmaceuticals has started patient enrolment in the Phase II HELIX-2 clinical trial designed for assessing an all-oral, direct-acting antiviral (DAA) hepatitis c virus (HCV) combination therapy of samatasvir, simeprevir and TMC647055 for the …

Daclatasvir and sofosbuvir (Sovaldi) with and without ribavirin for chronic hepatitis C infection

Daclatasvir in combination with sofosbuvir is intended to be used as first line therapy for the treatment of chronic hepatitis C infection with genotypes 1, 2, and 3. If licensed, this combination will provide an additional treatment option for this patient group, that does not require co-administration with interferon. Daclatasvir is a small molecule hepatitis C virus non-structural 5A (NS5A) rep...

UPDATE 1-US FDA approves Gilead's breakthrough hepatitis C drug

Dec 6 (Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi, also known as sofosbuvir, as a treatment for chronic infection with the liver-destroying hepatitis C virus.

FDA approves Gilead's breakthrough hepatitis C pill

(Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi, also known as sofosbuvir, as a potential cure for chronic infection with the liver-destroying hepatitis C virus.


Search BioPortfolio:
Advertisement

News Quicklinks

Advertisement